Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.

Trial Details

NCT ID
NCT07166263
Phase
EARLY_PHASE1
Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • NK510
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Aged ≥ 18 years, regardless of gender.
  • Gastric cancer and colorectal cancer that are inoperable and unresectable with radiotherapy: For gastric cancer, molecular diagnosis confirms that …
  • Progressive disease or recurrence after receiving ≥ 2 lines of treatment.
  • Patients are divided into two groups (Group A and Group B) based on the presence or absence of peritoneal metastasis. The criteria for determining …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →